Clozapine Shows Superior Response After First Antipsychotic Failure
Key Clinical Summary
- In a randomized clinical trial, 62.5% of first-episode psychosis (FEP) antipsychotic nonresponders with a diagnosis of schizophrenia, schizophreniform, or schizoaffective disorder achieved symptom response with clozapine vs 44.7% with amisulpride and 31.7% with olanzapine.
- Initial treatment response rates were highest with risperidone (63.4%) and amisulpride (61.8%), and lowest with aripiprazole (44.3%) and perphenazine (45.7%).
- Findings support considering clozapine earlier, after 1 failed antipsychotic trial in FEP.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic, according to recent study findings. The randomized clinical trial, published in JAMA Psychiatry, addresses ongoing clinical debate regarding optimal timing for clozapine initiation in early psychosis management.
Study Findings
The trial enrolled 762 participants aged 16 to 45 years, with 654 eligible for analysis (mean age 26.9 years; 50.2% male) recruited from 7 psychiatric institutions in China. In phase 1, patients were randomized to receive olanzapine, risperidone, amisulpride, aripiprazole, or perphenazine for 8 weeks. Among 556 participants who completed this phase, 359 (55.1%) achieved symptomatic response, defined as ≥40% reduction in Positive and Negative Syndrome Scale (PANSS) total score.
Response rates differed significantly across treatments (χ² = 18.3; P = .001). Risperidone (63.4%) and amisulpride (61.8%) demonstrated the highest efficacy, followed by olanzapine (60.5%). Lower response rates were observed with aripiprazole (44.3%) and perphenazine (45.7%).
In the second phase, 111 nonresponders were rerandomized to olanzapine (n=41), amisulpride (n=38), or clozapine (n=32) for an additional 8 weeks. Among 92 completers (82.9%), response rates were significantly higher with clozapine (62.5%) compared with amisulpride (44.7%) and olanzapine (31.7%) (χ² = 6.9; P = .03).
At 1-year follow-up, all-cause treatment discontinuation was high across both study phases. Of the patients enrolled in phase 1, 66.4% discontinued treatment, most commonly due to lack of efficacy, followed by nonadherence and adverse effects, with significant differences observed between treatment groups (P = .04).
Of the patients enrolled in phase 2, 64.0% discontinued during follow-up, but no significant between-group differences in all-cause discontinuation were detected.
Discontinuation remained substantial in a subgroup analysis of patients who initially responded to treatment, with a mean time to discontinuation of 132 days and an overall rate of 36.9%.
Clinical Implications
These findings inform both treatment selection and long-term management in first-episode psychosis. While most patients responded to initial therapy, particularly with risperidone and amisulpride, a substantial proportion required a second-line strategy, where clozapine demonstrated superior efficacy. This suggests clozapine may be considered earlier in the treatment sequence after a single failed antipsychotic trial.
However, the 1-year follow-up highlights a critical challenge: sustained treatment adherence. These findings underscore that early symptom response does not guarantee long-term treatment persistence. Clinically, this suggests that optimizing early efficacy must be paired with strategies to improve adherence and tolerability. Monitoring for adverse effects, addressing patient preferences, and proactive follow-up may be essential to reduce discontinuation risk and improve long-term outcomes in FEP.
Expert Commentary
“In this randomized clinical trial, results from the PANSS ratings suggest the superiority of clozapine for patients with FEP who have not responded adequately to a traditional antipsychotic and could have important implications for clinical practice,” wrote Xuan Li, MD, PhD, Division of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China, and study coauthors.
However, the researchers cautioned that the study’s small sample size and lack of effect on all-cause discontinuation highlight the need for future studies to confirm their findings.
“If it is imperative to obtain an early treatment response, this study provides some evidence for clinicians to consider using clozapine as the next sequential treatment after patients have failed an adequate trial with 1 of the more traditional antipsychotics,” they concluded.
